Business Wire

AMAZENTIS

17.5.2022 17:06:07 CEST | Business Wire | Press release

Share
New Milestone Clinical Study Shows Postbiotic Urolithin A (Mitopure™) Improves Muscle Strength and Exercise Performance in Middle Aged Adults

Amazentis, a spin-off of the Swiss Federal Institute of Technology (EPFL) pioneering scientific breakthroughs in cellular health and nutrition, announced today that the peer-reviewed clinical and translational journal Cell Reports Medicine published new clinical results showing the muscle health benefits of the gut microbiome postbiotic Urolithin A. Age-associated muscle decline can start as early as 40 years old and there are currently no effective interventions to counteract it other than exercise.

This milestone study showed that daily intake of Amazentis’ proprietary Urolithin A, Mitopure, significantly improved muscle strength by 12% after four months. These findings further validate Mitopure’s benefits for muscle and mitochondrial health and show it is safe and well tolerated. Mitopure works by supporting the cells’ ability to renew their powerplants, the mitochondria, during the aging process. Muscles have a high demand for energy and there are a very large number of mitochondria in muscle cells.

Previous research showed that Mitopure improved muscle endurance, reduced inflammation, and resulted in healthier mitochondrial function in older adults 65 to 90 years old. This new double-blind, placebo-controlled trial in middle-aged adults 40 to 64 years old (n=88) was conducted in London, Ontario, Canada following approvals from Health Canada and an independent IRB. Participants were randomized to receive daily supplementation with either 500mg, 1,000mg Mitopure or placebo for 4 months. Muscle strength, exercise performance tests and biomarkers of healthy mitochondrial function and inflammation in skeletal muscle biopsies and blood plasma were assessed at baseline, 2 months and 4 months.

  • Two measures of skeletal muscle strength were improved in the supplemented groups compared to the placebo group. Muscle strength in the hamstring skeletal muscle was significantly increased in both 500mg (+12%) and 1,000mg groups (+9.8%). Muscle strength during knee flexion was also significantly improved at both 500mg (+10.6%) and 1,000mg doses (+10.5%)
  • Clinically meaningful improvements on aerobic endurance (+ 10% in peak oxygen consumption [VO2]), physical performance (+ 33 meters on the 6 min walk test), and power output (+5%) were observed in the 1,000mg group, though not statistically significant
  • The blood tests and biopsies showed a significant improvement in biomarkers of healthy mitochondrial function and reduced inflammation

“These results are exciting because this is the first in human demonstration that Urolithin A repairs the mitochondria via mitophagy and can translate to meaningful physiological benefits. Furthermore, the improvement in strength and exercise-performance occurred in the absence of any changes to participants exercise routine,” explained Johan Auwerx, MD, PhD, co-author and Professor at the Swiss Federal Institute of Technology EPFL.

This is an important discovery in longevity and muscle health research. Aging is associated with a decline in mitochondrial function which can lead to reduced exercise capacity, muscle endurance and strength. Urolithin A is the first and only compound that has been clinically shown to improve muscle function by renewing the mitochondria through a potent biological quality control mechanism called mitophagy. By activating this important biological pathway, Mitopure promotes healthy aging and improved muscle health and performance.

“This study further validates the role of mitochondrial health as an important pillar of vitality and shows Mitopure is a first in class nutrient that meaningfully impacts muscle health. We are proud to offer this proprietary form of Urolithin A in our Timeline® brand and inside Nestlé Health Science products,” said Chris Rinsch, CEO and Co-Founder of Amazentis. “We remain committed to pioneering clinically validated products that optimize cellular health with the mission of keeping millions of people healthier for longer”.

In addition, Amazentis also announced that Dr. Eric Verdin has joined the Amazentis scientific advisory board. Dr. Verdin is the president and chief executive officer of the Buck Institute for Research on Aging and he has dedicated his career to studying longevity with the goal of transforming everyone into healthy centenarians.

“Mitochondrial decline is a key hallmark of aging and poor metabolic health. This study is an important milestone and shows that Urolithin A could be a gamechanger in our field.” said. Dr. Eric Verdin.

Doi: 10.1016/j.xcrm.2022.100633

About Amazentis
Amazentis is an innovative life sciences company employing today’s leading research and clinical science to develop the next generation of products targeting mitochondrial health for advanced nutrition. Amazentis has previously published its research on Mitopure™ Urolithin A in top peer reviewed scientific journals including Nature Medicine (doi:10.1038/nm.4132), Nature Metabolism (doi: 10.1038/s42255-019-0073-4), JAMA Network Open (doi:10.1001/jamanetworkopen.2021.44279) and European Journal of Clinical Nutrition (https://doi.org/10.1038/s41430-021-00950-1 ). The company has a global strategic partnership with Nestlé Health Science to expand the health applications of Mitopure™ linked to mitochondrial and cellular health. For more information on Amazentis, please visit www.amazentis.com .

About Mitopure™
Mitopure™ is a highly pure form of Urolithin A; a bioactive dietary metabolite that is produced by gut bacteria after eating certain foods, such as the pomegranate, though it is difficult for most people to get enough of this specialized nutrient from food alone. Mitopure™ has been shown to improve mitochondrial function by stimulating mitophagy, a process by which aging and damaged mitochondria are cleared from the cell, making way for healthy mitochondria to grow. Mitopure™ has been favorably reviewed by the U.S. Food and Drug Administration (FDA) and deemed safe following a GRAS (generally recognized as safe) filing. Mitopure™ has been extensively evaluated pre-clinically and clinically to support its use in humans for nutritional supplementation. For more information, please visit www.mitopure.com .

About Timeline®
Timeline® Nutrition is brought to you by the inventors of Mitopure™. This novel, science-first brand was developed by Amazentis on the belief that uncompromising research can unlock a new class of clinically validated nutritional products to optimize cellular health. For more information, please visit www.timelinenutrition.com .

Related Links
https://www.timelinenutrition.com
https://www.amazentis.com

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

ees Europe: Green Hydrogen: Opportunities and Production Ramp Up10.6.2026 16:13:00 CEST | Press release

For the major economies, the transformation towards a climate-neutral industry is one of the central tasks for the coming decades. While the European Union has pledged climate neutrality by 2050, China’s goal is to be climate-neutral by 2060. Hydrogen is a key to transforming their manufacturing and energy industry. However, the actual market development is lagging behind these ambitious objectives: According to the Global Energy Report 2025, only 11 percent of hydrogen projects announced since the start of the decade are now in operation or have been secured by investment decisions. This is why ees Europe, Europe’s largest and most international exhibition for batteries and energy storage systems, is putting a spotlight on hydrogen. The newly aligned exhibition segment Hydrogen Dialogue Forum & Expo in hall B2 will be giving in-depth information about the opportunities for hydrogen technology, technological innovation, savings potential and ground-breaking projects from June 23–25. Th

Info-Tech Research Group Recognizes Laserfiche as a Champion in the 2026 Enterprise Content Management – Enterprise Emotional Footprint Report10.6.2026 16:00:00 CEST | Press release

Laserfiche has been named a Champion for the enterprise category in the Enterprise Content Management Emotional Footprint 2026 Report by Info-Tech Research Group. Laserfiche — the leading SaaS provider of intelligent content management — was recognized based on reviews provided by end users. Laserfiche was recognized as a Champion for delivering significant business value, continued product innovation, and strong customer experience. “We are honored to be named a Champion by Info-Tech Research Group, which we believe underscores our relationships with our customers and commitment to their long-term success,” said Thomas Phelps, CIO and SVP of corporate strategy at Laserfiche. “We are grateful to our customers for partnering with us as we support their needs for AI-driven information management solutions. Of the 285 customers who completed an Info-Tech survey this year, 99% said they plan to renew.” Info-Tech Research Group’s Emotional Footprint report quantifies the end-user experience

BTG Pactual TIG Acquires Jamestown’s Timberland Platform10.6.2026 15:30:00 CEST | Press release

Acquisition includes approximately 90,000-acre U.S. timberland portfolio BTG Pactual Timberland Investment Group (BTG Pactual TIG), one of the world’s largest timberland investment managers, today announced the acquisition of approximately 90,000 acres of U.S. timberland formerly managed by Jamestown, a global design-focused real estate investment and management firm. The Jamestown timberland platform will be integrated into BTG Pactual TIG’s core U.S. timberland strategy’s portfolio. The portfolio of high-quality timberland spans five U.S. states, including approximately 50,000 acres of pine timberland in Georgia and Alabama and approximately 40,000 acres of diversified hardwood timberland across Indiana, Pennsylvania, and New York. All properties are certified under the Sustainable Forestry Initiative (SFI). The acquisition increases BTG Pactual TIG’s core U.S. timberland strategy’s portfolio to more than 1.7 million acres. The firm manages 3.3 million acres globally. The transaction

Solana Becomes Presenting Sponsor of the World Series of Poker®10.6.2026 15:00:00 CEST | Press release

WSOP to Bring Crypto to Global Events Through Solana-Powered Tournament Ticket Purchases The World Series of Poker (WSOP®), the longest-running and most prestigious poker tournament series in the world, today announced a first-of-its-kind collaboration with the Solana Foundation to bring crypto directly into the global poker experience. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260610344534/en/ The World Series of Poker TV production set in Las Vegas, presented by Solana Beginning today at the 57th annual summer event at Paris Las Vegas and Horseshoe Las Vegas, players will be able to purchase tournament tickets using Solana, powered by MoonPay’s payment infrastructure. This will be the first time in WSOP history where players can buy tournament tickets directly with crypto, and by leveraging Solana’s technology, this payment method will have zero processing fees. The integration will expand further at the 2026 WSOP Par

Capcom’s Dragon’s Dogma 2: Dark Arisen Scheduled to Launch on October 9, 2026!10.6.2026 15:00:00 CEST | Press release

– Capcom seeks to further broaden its user base through expansion content and a new platform launch – Capcom Co., Ltd. (TOKYO:9697) today announced that Dragon’s Dogma 2: Dark Arisen, which includes an expansion for Dragon’s Dogma 2, is scheduled to be released on October 9, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260610422753/en/ Dragon's Dogma 2: Dark Arisen logo The Dragon’s Dogma series consists of action games in a fantasy setting where players adventure in an expansive open world of swords and magic. Since the release of the first game in 2012, the series garnered praise worldwide for gameplay features such as its “pawn” adventure companions who can carry out actions on their own, leading the series to over 14 million* units sold cumulatively. Dragon’s Dogma 2: Dark Arisen is a paid expansion title that adds a new story to Dragon’s Dogma 2, which was released in March 2024. Based on the wide range of feedb

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye